| Authors: |
Soon YY; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Radiation Oncology, National University Cancer Institute, Singapore, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore., Marschner IC; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Schou M; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Sweeney CJ; South Australian Immunogenomics Cancer Institute, Adelaide, SA, Australia; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia; Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Australia., Davis ID; Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia; Eastern Health, Melbourne, VIC, Australia; Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Australia., Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Concord Repatriation General Hospital, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia; Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Australia., Martin AJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; UQ Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia; Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Australia. Electronic address: andrew.martin@uq.edu.au. |
